JK

Jay Keasling

Co-Founder

Apertor Pharmaceuticals

Therapeutic Areas

Apertor Pharmaceuticals Pipeline

DrugIndicationPhase
mTORC1 / 4EBP1 InterceptorNon Small Cell Lung CancerIND-Enabling
RAS Pathway InterceptorNon Small Cell Lung, Pancreatic, Colorectal CancerDiscovery
Undisclosed Target ProgramOncologyDiscovery